Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint-Reference-Cited by-同舟云学术

Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint

Published:2022-09 Issue: Volume:83 Page:104216
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Verma Navin Kumar^ORCID,Wong Brandon Han Siang,Poh Zhi Sheng,Udayakumar Aiswarya^ORCID,Verma Ritu^ORCID,Goh Ryan Kwang Jin,Duggan Shane P.,Shelat Vishalkumar G.^ORCID,Chandy K. George,Grigoropoulos Nicholas Francis

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference72 articles.

1. The three Es of cancer immunoediting;Dunn;Annu Rev Immunol,2004

2. Hallmarks of cancer: new dimensions;Hanahan;Cancer Discov,2022

3. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics;Twomey;AAPS J,2021

4. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade;Morad;Cell,2021

5. Tumour burden and efficacy of immune-checkpoint inhibitors;Dall'Olio;Nat Rev Clin Oncol,2022

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review;Journal of Drug Delivery Science and Technology;2024-10

2. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes;Molecular Cancer;2024-09-09

3. Engineered T cells for Colorectal Cancer;Immunotherapy;2024-09-04

4. Unleashing the potential of CD39-targeted cancer therapy: Breaking new ground and future prospects;Biomedicine & Pharmacotherapy;2024-09

5. Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy;Frontiers in Immunology;2024-08-30